Cross-Resistance: One Cancer Therapy Can Undermine the Next

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news